VGLUT3 gates psychomotor effects induced by amphetamine. 2019

Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
Neuroscience ParisSeine - Institut de Biologie Paris Seine (NPS - IBPS) INSERM, CNRS, Sorbonne Université, Paris, France.

Several subtypes of modulatory neurons co-express vesicular glutamate transporters (VGLUTs) in addition to their cognate vesicular transporters. These neurons are believed to establish new forms of neuronal communication. The atypical VGLUT3 is of particular interest since in the striatum this subtype is found in tonically active cholinergic interneurons (TANs) and in a subset of 5-HT fibers. The striatum plays a major role in psychomotor effects induced by amphetamine. Whether and how VGLUT3-operated glutamate/ACh or glutamate/5HT co-transmissions modulates psychostimulants-induced maladaptive behaviors is still unknown. Here, we investigate the involvement of VGLUT3 and glutamate co-transmission in amphetamine-induced psychomotor effects and stereotypies. Taking advantage of constitutive and cell-type specific VGLUT3-deficient mouse lines, we tackled the hypothesis that VGLUT3 could gate psychomotor effects (locomotor activity and stereotypies) induced by acute or chronic administration of amphetamine. Interestingly, VGLUT3-null mice demonstrated blunted amphetamine-induced stereotypies as well as reduced striatal ∆FosB expression. VGLUT3-positive varicosities within the striatum arise in part from 5HT neurons. We tested the involvement of VGLUT3 deletion in serotoninergic neurons in amphetamine-induced stereotypies. Mice lacking VGLUT3 specifically in 5HT fibers showed no alteration to amphetamine sensitivity. In contrast, specific deletion of VGLUT3 in cholinergic neurons partially phenocopied the effects observed in the constitutive knock-out mice. Our results show that constitutive deletion of VGLUT3 modulates acute and chronic locomotor effects induced by amphetamine. They point to the fact that the expression of VGLUT3 in multiple brain areas is pivotal in gating amphetamine-induced psychomotor adaptations. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.

UI MeSH Term Description Entries
D008124 Locomotion Movement or the ability to move from one place or another. It can refer to humans, vertebrate or invertebrate animals, and microorganisms. Locomotor Activity,Activities, Locomotor,Activity, Locomotor,Locomotor Activities
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000661 Amphetamine A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. Desoxynorephedrin,Levoamphetamine,Phenopromin,l-Amphetamine,Amfetamine,Amphetamine Sulfate,Amphetamine Sulfate (2:1),Centramina,Fenamine,Mydrial,Phenamine,Thyramine,levo-Amphetamine,Sulfate, Amphetamine,l Amphetamine,levo Amphetamine
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018345 Mice, Knockout Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes. Knockout Mice,Mice, Knock-out,Mouse, Knockout,Knock-out Mice,Knockout Mouse,Mice, Knock out
D026922 Amino Acid Transport Systems, Acidic Amino acid transporter systems capable of transporting acidic amino acids (AMINO ACIDS, ACIDIC). Acidic Amino Acid Transport Systems,Amino Acid Transport Systems, Anionic,Anionic Amino Acid Transport Systems,Acidic Amino Acid Transport Proteins,Acidic Amino Acid Transporters,Anionic Amino Acid Transport Proteins,Anionic Amino Acid Transporters

Related Publications

Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
November 1969, Archives internationales de pharmacodynamie et de therapie,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
October 1995, Progress in neuro-psychopharmacology & biological psychiatry,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
June 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
January 2011, Addiction biology,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
January 1973, La Vie medicale au Canada francais,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
January 1947, The American journal of psychology,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
December 1992, Brain research,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
December 1996, Behavioral neuroscience,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
May 1993, Brain research,
Nina Mansouri-Guilani, and Véronique Bernard, and Erika Vigneault, and Vincent Vialou, and Stéphanie Daumas, and Salah El Mestikawy, and Giuseppe Gangarossa
May 2003, Behavioural pharmacology,
Copied contents to your clipboard!